metabolic research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Surgery to attempt tumour removal is usually not possible or advisable for DIPG. By nature, these tumors invade diffusely throughout the brain stem, growing between normal nerve cells. Aggressive surgery would cause severe damage to neural structures vital for arm and leg movement, eye movement, swallowing, breathing, and even consciousness. A surgically performed brainstem biopsy for immunotyping of diffuse intrinsic pontine glioma has served a limited role in experimental clinical studies and treatment trials. However, recent studies have shown stereotactic needle biopsies can commonly be done safely and resulted in a histological diagnosis in 96.8% of cases. This has increased the frequency that biopsies have been used for diagnosis. This, however, is not the current standard of care for all patients, as it presents considerable risk depending on the biopsy location. The decision to do a biopsy is generally only done when medical imaging appears atypical enough that a different diagnosis is possible. Pontine biopsy is in no way a therapeutic or curative surgery, and the risks (potentially catastrophic and fatal) are only outweighed when the diagnosis is uncertain or the patient is enrolled in an approved clinical trial.
As part of the German High Command's preparations for Operation Barbarossa, Generaloberst Erich Hoepner was appointed to command the 4th Panzer Group in February 1941. It was to drive toward Leningrad as part of Army Group North under Wilhelm von Leeb. On 30 March 1941, Hitler delivered a speech to about two hundred senior Wehrmacht officers where he laid out his plans for an ideological war of annihilation (Vernichtungskrieg) against the Soviet Union. He stated that he "wanted to see the impending war against the Soviet Union conducted not according to the military principles, but as a war of extermination" against an ideological enemy, whether military or civilian. Many Wehrmacht leaders, including Hoepner, echoed the sentiment. As a commander of the 4th Panzer Group, he issued a directive to his troops:
== Medical uses == Cilostazol is approved for the treatment of intermittent claudication in the United States and United Kingdom. If no improvement is seen after 3 months, stopping the medication is reasonable. Cilostazol is also used for secondary stroke prevention, though to date no regulatory body has approved it specifically for that indication.
Sources: en.wikipedia.org
Required a retrievable record of all purchases, identifying the name and address of each party, to be kept for two years Required verification of proof of identity of all purchasers Required protection and disclosure methods in the collection of personal information Required reports to the Attorney General of any suspicious payments or disappearances of the regulated products Required training of employees with regard to the requirements of the CMEA. Retailers must self-certify as to training and compliance. The non-liquid dose form of regulated products may only be sold in unit dose blister packs Regulated products must be stored behind the counter or in a locked cabinet in such a way as to restrict public access Sales limits (per customer): Daily sales limit—must not exceed 3.6 grams of pseudoephedrine base without regard to the number of transactions 30-day (not monthly) sales limit—must not exceed 7.5 grams of pseudoephedrine base if sold by mail order or "mobile retail vendor" 30-day purchase limit—must not exceed 9 grams of pseudoephedrine base. (A misdemeanor possession offense under 21 U.S.C. § 844a for the person who buys it.) The requirements were revised in the Methamphetamine Production Prevention Act of 2008 to require that a regulated seller of scheduled listed chemical products may not sell such a product unless the purchaser:
=== Unconfirmed discovery claims === In late 1998, Polish physicist Robert Smolańczuk published calculations on the fusion of atomic nuclei towards the synthesis of superheavy atoms, including oganesson. His calculations suggested that it might be possible to make element 118 by fusing lead with krypton under carefully controlled conditions, and that the fusion probability (cross section) of that reaction would be close to the lead–chromium reaction that had produced element 106, seaborgium. This contradicted predictions that the cross sections for reactions with lead or bismuth targets would go down exponentially as the atomic number of the resulting elements increased. In 1999, researchers at Lawrence Berkeley National Laboratory made use of these predictions and announced the discovery of elements 118 and 116, in a paper published in Physical Review Letters, and very soon after the results were reported in Science. The researchers reported that they had performed the reaction
A safety review reported that deaths from tyramine/MAOI-induced hypertension are extremely rare and that no deaths from MAOI-induced hypertension had been reported in the medical literature for several decades. Phenelzine should not be combined with drugs that have significant serotonin reuptake inhibition or significant serotonin-releasing activity, because of the risk of serotonin toxicity. Examples include selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), clomipramine, imipramine, MDMA, and certain analgesics such as meperidine, tramadol, methadone, tapentadol, dextromethorphan, dextropropoxyphene, pentazocine, and levorphanol. This serotonin-toxicity mechanism is distinct from the usual caution about overlapping MAO-inhibiting agents. Classic MAOI-to-classic MAOI overlap is not expected to cause serotonin toxicity by itself, although routine long-term coadministration is generally avoided because of limited safety data and lack of usual therapeutic rationale. Indirect monoamine-releasing sympathomimetics without significant serotonergic activity, such as ephedrine and pseudoephedrine, are not absolute contraindications, but may increase blood pressure and are generally avoided or used only cautiously at reduced doses with monitoring. Pseudoephedrine is considered less potent than ephedrine, and ephedrine less potent than amphetamine.
baiH (7-β dehydratase): Downstream of baiG, the baiH gene encodes a 7-β dehydratase that has NADH:flavin oxidoreductase activity. This enzyme removes the carbon-carbon double bond introduced by baiCD. The connection between 7-β dehydratase and NADH was illuminated in a study that introduced a purified version of this protein into C. scindens, resulting in a decrease in the ratio of oxidized to reduced bile acid intermediates in the 7ɑ-dehydroxylation pathway. Since NAD+/NADH are electron carriers, these researchers assumed that this change in oxidized:reduced intermediate ratio indicated that 7-β dehydratase affected NADH levels. baiI (Δ-ketosteroid isomerase/7-β dehydratase): baiI, the furthest downstream gene of the bai operon, encodes for a protein that does not appear to be required for 7ɑ-dehydroxylation despite being highly conserved among different strains of Clostridium scindens. The classification of this protein is also under scrutiny, as some researchers believe it to have Δ-ketosteroid isomerase functionality while others believe it is a 7-β dehydratase like baiH.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.